The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness

Jorge Mestre-Ferrandiz;Patricia Deverka;Michele Pistollato;Emily Rosenberg

Occasional Paper from Office of Health Economics

Abstract: The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. A literature review helped elucidate concepts and define focus. The authors then conducted semi-structured interviews with an international sample of 19 senior pharmaceutical executives in various positions in the five companies: R&D, outcomes research, medical affairs, and pricing and reimbursement. The intent was to capture information about the effect of CER/RE requirements on the drug development process now and in the future.

Keywords: The; Current; Drug; Development; Paradigm:; Responding; to; US; and; European; Demands; for; Evidence; of; Comparative; Effectiveness; and; Relative; Effectiveness (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2014-04-01
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/current-drug-deve ... stre-ferrandiz-2014/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:occpap:000076

Access Statistics for this paper

More papers in Occasional Paper from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).